Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

J. de Bono

h-index 147 View on Semantic Scholar

We have 3 of 1,571 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial

Successful cancer immunotherapy requires not only tumor cell killing but also the activation of innate and adaptive immune responses. The inhibitor of apoptosis (IAP) proteins cIAP1, cIAP2 and XIAP act as key suppressors of RIPK1-driven immunogenic cell death, thereby enabling tumor immune evasion and limiting the ef...

C. Tiu, Wing Yau, T. Tenev et al. · 0 citations
Open access Sep 2026

Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic Therapies.

Variant histologic features can emerge in therapy-resistant prostate cancers, with treatment-emergent small-cell neuroendocrine carcinomas (t-SCNC) the most common. Here we report clinical, histopathological, and genomic features of 126 t-SCNCs and 14 other treatment-emergent variant histologies. This retrospective mul...

Nadeem Bilani, Jesenia M. Perez, Ana M. Aparicio et al. · 0 citations
Review Open access Jul 2026

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives

Delta-like ligand 3-directed therapies may reshape the management of DLL3-expressing prostate cancer if ongoing efforts to refine biomarkers improve patient enrichment and optimize trial design are successfully translated into clinical practice.

Giovanna Pecoraro, A. De Giorgi, G. Montelatici et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.